Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04984876 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
NCT04984876 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 211 participants.
The verdict
NCT04984876, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
Study Summary
This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection every 4 weeks) in participants with a medically confirmed diagnosis of Immunoglobulin E (IgE) mediated peanut allergy.
Interventions
- DRUG Placebo
- DRUG ligelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2021-12-07 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04984876
The ClinicalTrials.gov registry entry for NCT04984876 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04984876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04984876 about?
NCT04984876 is a clinical study titled "Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy". This was a 52-week, Phase 3 multi-center, randomized, double-blind and placebo-controlled study to assess the safety and clinical efficacy of two dosing regimens of ligelizumab (240 mg and 120 mg) SC q4w (subcutaneous injection every 4 weeks) in participants with a medically confirmed diagnosis of I...
What is the current status of trial NCT04984876?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2021-12-07. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT04984876?
The interventions under investigation include: Placebo (DRUG), ligelizumab (DRUG).
Who is sponsoring clinical trial NCT04984876?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.